Singapore-based StratifiCare is a medical company that develops and manufactures in vitro diagnostic medical devices, with a focus on personalized medicine. The company has developed a panel of biomarkers that can determine the risk of severe dengue, enabling physicians to provide personalized curative therapies to patients. With over 50 years of experience in biomedical R&D and technology commercialization, StratifiCare strives to empower personalized medicine by developing high-quality diagnostics in accordance with international quality standards. The company's goal is to support physicians in making informed decisions for individual patient care and improve clinical and socioeconomic outcomes.